Literature DB >> 35969263

[Clonal hematopoiesis: causes and clinical implications].

Andreas Burchert1.   

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) refers to hematopoiesis from stem cells with mutations in leukemia-associated driver genes. These confer increased stress tolerance and expansive potential to stem cell clones. Patients with CHIP are hematologically healthy. The main risk factor for the development of CHIP is age or chronic inflammatory processes associated with aging, so-called "inflammaging". Therefore, the correlation of age-associated comorbidities with the detection of CHIP is not coincidental. CHIP is associated with, among other things, a significantly increased risk of cardiovascular disease and increased all-cause mortality. From a pathomechanistic perspective, CHIP leads to increased secretion of proinflammatory cytokines. It is also associated with a significantly increased risk of developing hematologic neoplasms. Thus, the treatment of CHIP could suppress the occurrence of hematologic neoplasms and prevent age-associated diseases.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Cardiovascular comorbidity; Clonal hematopoiesis of indeterminate potential; Hematologic neoplasms; Inflammaging; Variant allele frequency

Year:  2022        PMID: 35969263     DOI: 10.1007/s00108-022-01388-8

Source DB:  PubMed          Journal:  Inn Med (Heidelb)        ISSN: 2731-7080


  42 in total

1.  Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years.

Authors:  Isabelle A van Zeventer; Jonas B Salzbrunn; Aniek O de Graaf; Bert A van der Reijden; H Marike Boezen; Judith M Vonk; Pim van der Harst; Jan Jacob Schuringa; Joop H Jansen; Gerwin Huls
Journal:  Blood Adv       Date:  2021-04-27

Review 2.  In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions.

Authors:  Serena Scala; Alessandro Aiuti
Journal:  Blood Adv       Date:  2019-06-25

3.  Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life.

Authors:  Rocio Acuna-Hidalgo; Hilal Sengul; Marloes Steehouwer; Maartje van de Vorst; Sita H Vermeulen; Lambertus A L M Kiemeney; Joris A Veltman; Christian Gilissen; Alexander Hoischen
Journal:  Am J Hum Genet       Date:  2017-06-29       Impact factor: 11.025

4.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.

Authors:  Florian Zink; Simon N Stacey; Gudmundur L Norddahl; Michael L Frigge; Olafur T Magnusson; Ingileif Jonsdottir; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Sigurjon A Gudjonsson; Julius Gudmundsson; Jon G Jonasson; Laufey Tryggvadottir; Thorvaldur Jonsson; Agnar Helgason; Arnaldur Gylfason; Patrick Sulem; Thorunn Rafnar; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Gisli Masson; Augustine Kong; Kari Stefansson
Journal:  Blood       Date:  2017-05-08       Impact factor: 22.113

5.  DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.

Authors:  Manuel Buscarlet; Sylvie Provost; Yassamin Feroz Zada; Amina Barhdadi; Vincent Bourgoin; Guylaine Lépine; Luigina Mollica; Natasha Szuber; Marie-Pierre Dubé; Lambert Busque
Journal:  Blood       Date:  2017-06-27       Impact factor: 22.113

6.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

7.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

8.  Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis.

Authors:  Thomas McKerrell; Naomi Park; Thaidy Moreno; Carolyn S Grove; Hannes Ponstingl; Jonathan Stephens; Charles Crawley; Jenny Craig; Mike A Scott; Clare Hodkinson; Joanna Baxter; Roland Rad; Duncan R Forsyth; Michael A Quail; Eleftheria Zeggini; Willem Ouwehand; Ignacio Varela; George S Vassiliou
Journal:  Cell Rep       Date:  2015-02-26       Impact factor: 9.423

9.  Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis.

Authors:  Henne Holstege; Wayne Pfeiffer; Daoud Sie; Marc Hulsman; Thomas J Nicholas; Clarence C Lee; Tristen Ross; Jue Lin; Mark A Miller; Bauke Ylstra; Hanne Meijers-Heijboer; Martijn H Brugman; Frank J T Staal; Gert Holstege; Marcel J T Reinders; Timothy T Harkins; Samuel Levy; Erik A Sistermans
Journal:  Genome Res       Date:  2014-04-23       Impact factor: 9.043

10.  Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.

Authors:  Lambert Busque; Jay P Patel; Maria E Figueroa; Aparna Vasanthakumar; Sylvie Provost; Zineb Hamilou; Luigina Mollica; Juan Li; Agnes Viale; Adriana Heguy; Maryam Hassimi; Nicholas Socci; Parva K Bhatt; Mithat Gonen; Christopher E Mason; Ari Melnick; Lucy A Godley; Cameron W Brennan; Omar Abdel-Wahab; Ross L Levine
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.